Compare Estee Lauder Companies Inc (EL) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Health Care Select Sector SPDR Fund — how do they compare? Estee Lauder Companies Inc trades at $87.6 (market cap $31.76B), while Health Care Select Sector SPDR Fund trades at $167.83. The key difference: Estee Lauder Companies Inc pays a 1.59% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Estee Lauder Companies Inc nearer its low. Which is the better fit depends on your goals.
| EL | XLV | |
|---|---|---|
Market Cap | $31.76B | — |
Sector | Consumer Staples | — |
52-Week High | $119.61 | $168.44 |
52-Week Low | $67.23 | $131.16 |
Enterprise Value | $37.93B | — |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $87.19, down 1.31% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with a net loss of $1.13B in 2025 and negative profit margins, though recent quarters have consistently beaten EPS expectations. Analyst sentiment is divided with a Hold consensus and $91.67 price target, while institutional activity shows significant position changes including Bank of America's 950.9% stake increase in Q1 2026.
The stock presents a recovery opportunity with strong brand positioning and recent product launches like the Glimmer fragrance, but faces headwinds from declining revenues and profitability. Near-term catalysts include the upcoming Q2 2026 earnings report where EL is expected to post $0.3193 EPS. The key risk remains execution on margin improvement amid competitive pressures in the beauty sector.
XLV, the Health Care Select Sector SPDR ETF, trades at $167.1, down 0.8% on the day. The technical outlook is bullish based on moving averages, though short-term oscillators signal overbought conditions. Recent news highlights the ETF's defensive appeal amid economic uncertainty and its competitive edge with a low 0.08% expense ratio. Strong healthcare earnings and investor inflows into defensive sectors support positive momentum.
The outlook for XLV is positive, driven by defensive sector demand and solid underlying holdings. Key opportunities include cost efficiency and diversification across 60 healthcare stocks. Risks involve sector-specific pressures like regulatory changes and liquidity challenges. Analyst sentiment remains favorable, with the ETF well-positioned for steady growth in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
